About this trial
Albumin/globulin ratio and platelet/albumin ratio as a predictive non-invasive biomarker for lupus nephritis (LN) presence and severity
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients aged 18 years or older diagnosed as SLE according to 2019 ACR/EULAR classification criteria and with lupus nephritis (LN) according to the ACR criteria.
Patients with available baseline laboratory investigations and renal biopsy.
Disqualifiers
Patients with chronic liver disease, hematological disorders, or malignancies affecting albumin/globulin ratio or platelet counts.
Patients on nephrotoxic medications not related to SLE management.
Recent infections or acute inflammatory conditions.
Trial population
Aged ≥18 years. * SLE patients fulfilling the SLE International Collaborating Clinics (SLICC) - ----classification criteria and matched controls. * Patients cooperative and can answer questions. * Patients who are able and willing to give written informed consent.
Trial design
Cohort
Cross-sectional
Treatments tested in this trial
Not listed
Trial groups
Trial outcomes
Primary outcomes
Association of Albumin/Globulin (A/G) and Platelet/ Albumin (P/A) ratios with the presence of lupus nephritis
unit of measurments : ratios (no units )
Compare the Albumin/Globulin (A/G) and Platelet/Albumin (P/A) ratios between different classes of lupus nephritis
unite of measurments : ratios (no units )
Secondary outcomes
• Correlation of A/G and P/A ratios with lupus nephritis class, 24-hour urine protein or urine protein/creatinine ratio, Serum creatinine and eGFR.
• Predictive value of A/G and P/A ratios for renal involvement: Using logistic regression or ROC curve analysis to assess whether these ratios can predict the presence of nephritis.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: